Everything we've seen

1. ?Nov 13, 3:25 PMdecisionconsidered

   Agent 7 — Day Trader — decide: skip

   MDT is up 1.89% with only 20 minutes remaining until the forced close. The move is meaningful but not extreme. The critical issue is the extremely limited time horizon — with only 20 minutes left, even a strong momentum setup has very little room to run to the +3% profit target, and the probability of meaningful continuation compresses sharply. The macro context shows a flattening yield curve (T10Y2Y 2.0σ below trend), which is a mild tailwind for defensives like MDT (healthcare/medical devices), but this effect is marginal at this time scale. No headlines are present to explain the move, which is neutral per guidance. However, the combination of (1) very little time remaining, (2) a move that is already largely priced in mid-session without a clear catalyst, and (3) the risk that late-session profit-taking or mean reversion kicks in over the final 20 minutes all argue for caution. The setup does not meet the threshold for a position given the time constraint effectively neutralizes the momentum edge.

2. !Nov 13, 3:25 PMsignalseverity 0.02

   Agent 7 — Day Trader — day_trade_skipped

   MDT is up 1.89% with only 20 minutes remaining until the forced close. The move is meaningful but not extreme. The critical issue is the extremely limited time horizon — with only 20 minutes left, even a strong momentum setup has very little room to run to the +3% profit target, and the probability of meaningful continuation compresses sharply. The macro context shows a flattening yield curve (T10Y2Y 2.0σ below trend), which is a mild tailwind for defensives like MDT (healthcare/medical devices), but this effect is marginal at this time scale. No headlines are present to explain the move, which is neutral per guidance. However, the combination of (1) very little time remaining, (2) a move that is already largely priced in mid-session without a clear catalyst, and (3) the risk that late-session profit-taking or mean reversion kicks in over the final 20 minutes all argue for caution. The setup does not meet the threshold for a position given the time constraint effectively neutralizes the momentum edge.

3. ?Nov 13, 1:55 PMdecisionconsidered

   Agent 7 — Day Trader — decide: skip

   MDT is up 2.09% today with no attributable headline, suggesting institutional flow or sector rotation rather than a news-driven pop that might fade quickly. With 110 minutes remaining there is meaningful time for continuation. However, the macro context is a mild headwind: the T10Y2Y spread is 2.0σ below its 24-month trend (flattening/near-inversion), which typically favors defensives broadly — MDT as a large-cap medical device name has some defensive characteristics, so this could actually be supportive of the move rather than a detractor. No reversal signals or fade patterns are noted. The move is at the lower bound of the 2-5% 'meaningful flow' range, so conviction is moderate but not strong. No news absence penalty applied per guidance. Overall, modest continuation probability — no strong reason to expect fade, but no particularly high-conviction tailwind either.

4. !Nov 13, 1:55 PMsignalseverity 0.02

   Agent 7 — Day Trader — day_trade_skipped

   MDT is up 2.09% today with no attributable headline, suggesting institutional flow or sector rotation rather than a news-driven pop that might fade quickly. With 110 minutes remaining there is meaningful time for continuation. However, the macro context is a mild headwind: the T10Y2Y spread is 2.0σ below its 24-month trend (flattening/near-inversion), which typically favors defensives broadly — MDT as a large-cap medical device name has some defensive characteristics, so this could actually be supportive of the move rather than a detractor. No reversal signals or fade patterns are noted. The move is at the lower bound of the 2-5% 'meaningful flow' range, so conviction is moderate but not strong. No news absence penalty applied per guidance. Overall, modest continuation probability — no strong reason to expect fade, but no particularly high-conviction tailwind either.

5. ?Nov 13, 12:15 PMdecisionconsidered

   Agent 7 — Day Trader — decide: skip

   MDT is up 2.02% intraday with no headline catalyst visible, suggesting this is likely institutional flow or sector rotation into defensives. The macro context is notable: T10Y2Y at 2.0σ below trend indicates a flattening/near-inversion environment, which historically benefits defensive sectors like Healthcare/MedTech (MDT's space) as investors seek safety. This provides a mild tailwind for continuation. With 210 minutes remaining (roughly 3.5 hours), there is ample time for the move to extend. However, the absence of a specific catalyst means the move could be headline-driven by something not yet captured, or pure technical/flow-driven momentum that may fade as the session matures. The 2% move is meaningful but not extreme, suggesting the move hasn't exhausted itself. No reversal pattern is evident from the data provided. Balancing the supportive macro backdrop for defensives, sufficient time remaining, and lack of a clear fade signal against the absence of a news catalyst and no volume confirmation data, a modest continuation probability above the threshold is warranted.

6. !Nov 13, 12:15 PMsignalseverity 0.02

   Agent 7 — Day Trader — day_trade_skipped

   MDT is up 2.02% intraday with no headline catalyst visible, suggesting this is likely institutional flow or sector rotation into defensives. The macro context is notable: T10Y2Y at 2.0σ below trend indicates a flattening/near-inversion environment, which historically benefits defensive sectors like Healthcare/MedTech (MDT's space) as investors seek safety. This provides a mild tailwind for continuation. With 210 minutes remaining (roughly 3.5 hours), there is ample time for the move to extend. However, the absence of a specific catalyst means the move could be headline-driven by something not yet captured, or pure technical/flow-driven momentum that may fade as the session matures. The 2% move is meaningful but not extreme, suggesting the move hasn't exhausted itself. No reversal pattern is evident from the data provided. Balancing the supportive macro backdrop for defensives, sufficient time remaining, and lack of a clear fade signal against the absence of a news catalyst and no volume confirmation data, a modest continuation probability above the threshold is warranted.

7. ?Nov 13, 10:35 AMdecisionconsidered

   Agent 7 — Day Trader — decide: skip

   MDT is up 2.05% intraday with no headline catalyst visible, suggesting this is likely driven by institutional flow or sector rotation into defensive/healthcare names. With 310 minutes remaining (well over 5 hours), there is ample time for the move to continue into the close. The macro context (T10Y2Y at 2σ below 24-month trend, a flatter/inverted curve) is modestly supportive of defensive sectors like healthcare/medtech, as a flatter yield curve tends to push rotation toward defensives. However, the absence of a specific news catalyst means this move could be mean-reverting, and the 2% gain already achieved narrows the remaining upside before hitting the +3% profit target. No clear reversal signals are present. On balance, the move has moderate continuation probability — no strong reason to expect fade, modest macro tailwind for defensives, and plenty of time remaining — but conviction is not high given the lack of a named catalyst and the already meaningful intraday gain.

8. !Nov 13, 10:35 AMsignalseverity 0.02

   Agent 7 — Day Trader — day_trade_skipped

   MDT is up 2.05% intraday with no headline catalyst visible, suggesting this is likely driven by institutional flow or sector rotation into defensive/healthcare names. With 310 minutes remaining (well over 5 hours), there is ample time for the move to continue into the close. The macro context (T10Y2Y at 2σ below 24-month trend, a flatter/inverted curve) is modestly supportive of defensive sectors like healthcare/medtech, as a flatter yield curve tends to push rotation toward defensives. However, the absence of a specific news catalyst means this move could be mean-reverting, and the 2% gain already achieved narrows the remaining upside before hitting the +3% profit target. No clear reversal signals are present. On balance, the move has moderate continuation probability — no strong reason to expect fade, modest macro tailwind for defensives, and plenty of time remaining — but conviction is not high given the lack of a named catalyst and the already meaningful intraday gain.

9. ?Nov 10, 10:50 AMdecisionconsidered

   Agent 7 — Day Trader — decide: skip

   MDT is down 1.61% intraday, which is a moderate but not dramatic move. No headlines are present to explain the move, so it may reflect broader sector rotation or quiet institutional selling. The macro context shows the fed funds rate running 2.0σ above its 24-month trend, which is modestly negative for rate-sensitive healthcare/medtech names like MDT — elevated rates compress multiples and increase discount rates on long-duration cash flows. However, with 295 minutes remaining (nearly a full session still ahead), this is actually a lot of time for the move to either continue or reverse. The move magnitude (~1.6%) is below the threshold that typically signals strong conviction flows, and without a catalyst the drift may fade as algos and mean-reversion desks step in. On balance, there is mild continuation pressure from the macro rate headwind and the existing downward momentum, but nothing strongly compelling. This sits at the borderline — assigning 0.50 as a neutral read with slight downward lean given macro context but no strong conviction signals.

10. !Nov 10, 10:50 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    MDT is down 1.61% intraday, which is a moderate but not dramatic move. No headlines are present to explain the move, so it may reflect broader sector rotation or quiet institutional selling. The macro context shows the fed funds rate running 2.0σ above its 24-month trend, which is modestly negative for rate-sensitive healthcare/medtech names like MDT — elevated rates compress multiples and increase discount rates on long-duration cash flows. However, with 295 minutes remaining (nearly a full session still ahead), this is actually a lot of time for the move to either continue or reverse. The move magnitude (~1.6%) is below the threshold that typically signals strong conviction flows, and without a catalyst the drift may fade as algos and mean-reversion desks step in. On balance, there is mild continuation pressure from the macro rate headwind and the existing downward momentum, but nothing strongly compelling. This sits at the borderline — assigning 0.50 as a neutral read with slight downward lean given macro context but no strong conviction signals.

11. ?Nov 6, 2:16 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    MDT is down 2.34% intraday with no attributable headline, suggesting either sector rotation or broad market pressure. The macro context (elevated mortgage rates at 1.9σ above trend) is not directly relevant to MDT as a medical device company, so no meaningful macro tailwind or headwind applies here. With 90 minutes remaining, there is enough time for continuation but also enough time for a mean-reversion bounce, particularly after a move of this magnitude with no clear catalyst. The absence of news cuts both ways — no panic seller narrative, but also no resolution catalyst to reverse the move. The move is meaningful and represents real flow, so momentum bias leans toward continuation, but the lack of sector context, no news driver, and the moderate-to-large magnitude of the move (which raises fade risk as late-day profit-taking or covering kicks in) keeps conviction limited. Assigning 0.50 as a borderline read — slight momentum bias toward continuation but no strong conviction to push higher.

12. !Nov 6, 2:16 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    MDT is down 2.34% intraday with no attributable headline, suggesting either sector rotation or broad market pressure. The macro context (elevated mortgage rates at 1.9σ above trend) is not directly relevant to MDT as a medical device company, so no meaningful macro tailwind or headwind applies here. With 90 minutes remaining, there is enough time for continuation but also enough time for a mean-reversion bounce, particularly after a move of this magnitude with no clear catalyst. The absence of news cuts both ways — no panic seller narrative, but also no resolution catalyst to reverse the move. The move is meaningful and represents real flow, so momentum bias leans toward continuation, but the lack of sector context, no news driver, and the moderate-to-large magnitude of the move (which raises fade risk as late-day profit-taking or covering kicks in) keeps conviction limited. Assigning 0.50 as a borderline read — slight momentum bias toward continuation but no strong conviction to push higher.

13. ?Oct 15, 10:40 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    MDT is up 1.62% today — a moderate but meaningful move suggesting real buying interest. No news is available to explain the move, which is common; the flow itself is the signal. However, several factors temper enthusiasm: (1) The 5-year forward inflation rate (T5YIFR) is running 1.6σ above trend, indicating elevated rate expectations that create a headwind for rate-sensitive sectors. MDT as a large-cap medical device company carries meaningful duration/rate sensitivity in its valuation, making it somewhat vulnerable to this macro backdrop. (2) The move at 1.62% is real but not strong enough to suggest a high-conviction squeeze or catalyst-driven surge. (3) With 305 minutes remaining (essentially a full afternoon session), there is ample time for the move to either extend or mean-revert, but the lack of a clear catalyst means the move could fade as afternoon participants take profits. Balancing the positive momentum signal against the mildly adverse macro rate context and absence of a fundamental driver, this reads as a modest continuation setup. The asymmetric risk structure (tight stop, fixed target, bounded loss) justifies taking the trade at a narrow edge.

14. !Oct 15, 10:40 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    MDT is up 1.62% today — a moderate but meaningful move suggesting real buying interest. No news is available to explain the move, which is common; the flow itself is the signal. However, several factors temper enthusiasm: (1) The 5-year forward inflation rate (T5YIFR) is running 1.6σ above trend, indicating elevated rate expectations that create a headwind for rate-sensitive sectors. MDT as a large-cap medical device company carries meaningful duration/rate sensitivity in its valuation, making it somewhat vulnerable to this macro backdrop. (2) The move at 1.62% is real but not strong enough to suggest a high-conviction squeeze or catalyst-driven surge. (3) With 305 minutes remaining (essentially a full afternoon session), there is ample time for the move to either extend or mean-revert, but the lack of a clear catalyst means the move could fade as afternoon participants take profits. Balancing the positive momentum signal against the mildly adverse macro rate context and absence of a fundamental driver, this reads as a modest continuation setup. The asymmetric risk structure (tight stop, fixed target, bounded loss) justifies taking the trade at a narrow edge.

15. ?Oct 12, 6:21 PMdecisionconsidered

    Agent 20 — SIR Price/Volume — buy

    [not executed — reserve_floor_or_cash] [cluster_break_up] From 2026-09-29 through 2026-10-07, MDT carved out a dense price cluster in the $85.51–$87.97 range on progressively expanding volume (peaking at 55.9M on 2026-10-07), consistent with a high-volume shakeout/compression base rather than sustained distribution. The pivotal session of 2026-10-08 saw a massive 105.7M-share up-day — nearly 4× the trailing 20-day ADV of 27.9M — that lifted the close to $87.75, signaling aggressive demand absorbing the float built up during the cluster. Over the subsequent two sessions (2026-10-09 at $88.48 and today 2026-10-12 at $91.93 on 36.6M shares, +3.90%), the PV path has moved decisively up-and-right away from the cluster zone, breaking well above the September highs near $92–$93, which is a classic SIR cluster_break_up resolution where fresh demand clears the accumulated supply. Risks: A reversal back below the breakout cluster floor (~$87–$88) on elevated volume would strongly invalidate the bullish read, suggesting the 2026-10-08 surge was a one-day liquidity event (e.g., index rebalancing or short-covering) rather than genuine accumulation. Additionally, the macro backdrop — with T10Y3M at 1.6σ above trend — introduces recession-sensitivity risk for Health Care / MDT if yield-curve signals deteriorate further and compress sector multiples.

16. ?Oct 12, 10:40 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    MDT is up 3.13% today with no attributable headline, suggesting institutional flow or sector rotation driving the move. With 305 minutes remaining (roughly 5 hours), there is ample time for continuation into the close. The macro context shows the 10Y-3M spread at 0.99 (1.6σ above trend), which is mildly positive for risk assets but primarily flagged as relevant for banks and recession-sensitive sectors — MDT as a large-cap medtech is only indirectly affected and not meaningfully headwind. No news means no catalyst exhaustion to fade against. The 3.13% move is at the lower bound of the 'meaningful conviction' range, so momentum is real but not extreme. No reversal pattern or fade signal is evident from the data provided. Overall, this is a borderline-but-leaning continuation setup: no reason to fade, some reason to follow, but limited signal clarity warrants a modest probability above threshold rather than a high-conviction read.

17. !Oct 12, 10:40 AMsignalseverity 0.03

    Agent 7 — Day Trader — day_trade_skipped

    MDT is up 3.13% today with no attributable headline, suggesting institutional flow or sector rotation driving the move. With 305 minutes remaining (roughly 5 hours), there is ample time for continuation into the close. The macro context shows the 10Y-3M spread at 0.99 (1.6σ above trend), which is mildly positive for risk assets but primarily flagged as relevant for banks and recession-sensitive sectors — MDT as a large-cap medtech is only indirectly affected and not meaningfully headwind. No news means no catalyst exhaustion to fade against. The 3.13% move is at the lower bound of the 'meaningful conviction' range, so momentum is real but not extreme. No reversal pattern or fade signal is evident from the data provided. Overall, this is a borderline-but-leaning continuation setup: no reason to fade, some reason to follow, but limited signal clarity warrants a modest probability above threshold rather than a high-conviction read.

18. ?Oct 9, 9:55 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    MDT is up 1.67% today, a meaningful but not outsized move. There are no recent headlines to explain the move, suggesting it may be driven by broader market flows or sector rotation rather than a specific catalyst — this is neutral, not disqualifying. The macro context (elevated mortgage rates at 7.4%, 3.8σ above trend) is most relevant to Homebuilders, REITs, and Banks, not medical devices/healthcare, so MDT is largely insulated from that headwind. With 350 minutes remaining (well before the close), there is ample time for continuation. However, the absence of a clear catalyst and the modest move magnitude (below the 2% threshold where conviction becomes more compelling) keep this in the ordinary momentum bucket. No reversal signals are evident. Taking a mild lean toward continuation given the time available, bounded risk parameters, and no countervailing sector pressure.

19. !Oct 9, 9:55 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    MDT is up 1.67% today, a meaningful but not outsized move. There are no recent headlines to explain the move, suggesting it may be driven by broader market flows or sector rotation rather than a specific catalyst — this is neutral, not disqualifying. The macro context (elevated mortgage rates at 7.4%, 3.8σ above trend) is most relevant to Homebuilders, REITs, and Banks, not medical devices/healthcare, so MDT is largely insulated from that headwind. With 350 minutes remaining (well before the close), there is ample time for continuation. However, the absence of a clear catalyst and the modest move magnitude (below the 2% threshold where conviction becomes more compelling) keep this in the ordinary momentum bucket. No reversal signals are evident. Taking a mild lean toward continuation given the time available, bounded risk parameters, and no countervailing sector pressure.

20. ?Oct 8, 6:21 PMdecisionconsidered

    Agent 20 — SIR Price/Volume — skip

    [exhaustion] The 20-day PV path tells a story of persistent distribution morphing into a potential climax: from 2026-09-18 through 2026-10-07, MDT traced a clear down-and-right drift — price sliding from $92.13 to $85.51 while daily volume relentlessly expanded from 15.4M to 55.9M, a textbook bearish drift. Today's bar (2026-10-08, close $87.75, volume 105.7M, z-score +5.60) is a dramatic single-session volume spike — nearly 5× the trailing 20-day ADV of 21.0M — occurring right at a price level ($87–$88) that served as a congestion floor during the Sep 23–25 cluster. While the +2.62% close is encouraging on its face, SIR methodology flags this as a potential exhaustion / selling-climax event rather than a clean cluster_break_up: the preceding multi-session path was down-and-right, not a quiet low-volume cluster, and the unprecedented volume spike on a single up-day lacks multi-session confirmation of sustained demand absorption. Risks: This read would be invalidated if the next 2–3 sessions see MDT hold above $86.50–$87.00 on declining but still above-average volume, confirming today's spike as genuine accumulation rather than a one-day relief rally into still-active distribution; a swift reclaim and close above the $90–$92 prior cluster zone with sustained volume would fully negate the bearish path read.

21. ?Oct 8, 11:30 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    MDT is up 2.03% intraday with no attributable headline, suggesting institutional flow or sector rotation rather than a news-driven spike. The move is meaningful but not extreme — real conviction, but not the kind of blowoff that typically invites aggressive fading. Macro context shows the 5Y5Y forward inflation rate (T5YIFR) at 1.8σ above trend, which is modestly hawkish for rates. MDT as a large-cap medtech/device name has some rate sensitivity (higher discount rates weigh on growth-oriented healthcare), so elevated inflation expectations could act as a mild headwind and cap further upside. However, this macro signal is not strongly sector-specific enough to call an outright fade. With 255 minutes remaining (essentially the full afternoon session), there is ample time for continuation if the underlying bid persists. No reversal pattern or volume concern is evident from available data. Balancing the moderate-magnitude move, mild macro headwind from elevated forward inflation expectations, absence of negative catalysts, and sufficient time remaining, a modest continuation probability is warranted — not high-conviction, but enough to favor the long side given bounded risk parameters.

22. !Oct 8, 11:30 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    MDT is up 2.03% intraday with no attributable headline, suggesting institutional flow or sector rotation rather than a news-driven spike. The move is meaningful but not extreme — real conviction, but not the kind of blowoff that typically invites aggressive fading. Macro context shows the 5Y5Y forward inflation rate (T5YIFR) at 1.8σ above trend, which is modestly hawkish for rates. MDT as a large-cap medtech/device name has some rate sensitivity (higher discount rates weigh on growth-oriented healthcare), so elevated inflation expectations could act as a mild headwind and cap further upside. However, this macro signal is not strongly sector-specific enough to call an outright fade. With 255 minutes remaining (essentially the full afternoon session), there is ample time for continuation if the underlying bid persists. No reversal pattern or volume concern is evident from available data. Balancing the moderate-magnitude move, mild macro headwind from elevated forward inflation expectations, absence of negative catalysts, and sufficient time remaining, a modest continuation probability is warranted — not high-conviction, but enough to favor the long side given bounded risk parameters.

23. ?Oct 8, 10:05 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    MDT is up 1.78% today without a clear news catalyst, suggesting institutional flow or sector rotation rather than a headline-driven spike. The move is meaningful but not large enough (sub-2%) to strongly imply exhaustion or a fade. Macro context shows 5-year forward inflation expectations elevated at 1.8σ above trend — this is mildly negative for rate-sensitive sectors like medical devices (which carry valuation sensitivity to discount rates), creating a modest headwind for continuation. However, absence of news does not disqualify the move; real flow is in play. With 340 minutes remaining (essentially the full afternoon session), there is ample time for continuation if buyers remain engaged. No reversal signals are identifiable from available data. Balancing the mild macro headwind from elevated inflation expectations against the real momentum signal and available time, probability is just above the 0.5 threshold — a borderline continuation setup.

24. !Oct 8, 10:05 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    MDT is up 1.78% today without a clear news catalyst, suggesting institutional flow or sector rotation rather than a headline-driven spike. The move is meaningful but not large enough (sub-2%) to strongly imply exhaustion or a fade. Macro context shows 5-year forward inflation expectations elevated at 1.8σ above trend — this is mildly negative for rate-sensitive sectors like medical devices (which carry valuation sensitivity to discount rates), creating a modest headwind for continuation. However, absence of news does not disqualify the move; real flow is in play. With 340 minutes remaining (essentially the full afternoon session), there is ample time for continuation if buyers remain engaged. No reversal signals are identifiable from available data. Balancing the mild macro headwind from elevated inflation expectations against the real momentum signal and available time, probability is just above the 0.5 threshold — a borderline continuation setup.

25. ?Oct 8, 7:00 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MDT is a large-cap medtech incumbent (Medtronic) with a historically stable business, so the 10.2% dip from its 30-day high is not anomalous by triage standards and likely reflects sector-wide pressure rather than company-specific deterioration. However, Health Care (XLV) is notably underperforming — ranked 5th of 11 by 30-day relative strength and down -6.40pts vs SPY over 30 days — suggesting MDT is partially caught in a sector-wide sell-off with no identifiable company-specific recovery catalyst visible. The 10Y yield at 5.31% is a meaningful headwind for a dividend-heavy medtech name, and the elevated 5Y forward inflation rate (1.8σ above trend) adds macro pressure. Earnings are 40 days out (non-factor per framework), and there are no insider buys, no unusual call flow, and no SEC filing metrics to anchor fundamental stability or a recovery thesis.

26. !Oct 8, 7:00 AMsignalseverity 0.10

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MDT is a large-cap medtech incumbent (Medtronic) with a historically stable business, so the 10.2% dip from its 30-day high is not anomalous by triage standards and likely reflects sector-wide pressure rather than company-specific deterioration. However, Health Care (XLV) is notably underperforming — ranked 5th of 11 by 30-day relative strength and down -6.40pts vs SPY over 30 days — suggesting MDT is partially caught in a sector-wide sell-off with no identifiable company-specific recovery catalyst visible. The 10Y yield at 5.31% is a meaningful headwind for a dividend-heavy medtech name, and the elevated 5Y forward inflation rate (1.8σ above trend) adds macro pressure. Earnings are 40 days out (non-factor per framework), and there are no insider buys, no unusual call flow, and no SEC filing metrics to anchor fundamental stability or a recovery thesis.

27. ?Oct 8, 7:00 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    MDT passes the hard veto check — earnings are 40 days away (not imminent), no fundamental deterioration is visible in the sparse SEC filings, and no going-concern language is present. However, the net signal score is weak: the sector (XLV) is underperforming SPY meaningfully (-6.40pts over 30 days, +1), and there are no insider buys, no unusual call flow, and the drop is only 10.2% (below the 15% mean-reversion threshold). Against those modest positives, the 10Y yield at 5.31% is a structural headwind for a duration-sensitive medtech name (-1), earnings in 15-30 days is not applicable but the 40-day window still introduces uncertainty, elevated 5Y forward inflation expectations (T5YIFR at 1.8σ above trend) add macro pressure (-1), and the re-entry context is critical — the prior trade exited at $93.38, and at $85.69 the stock is still well below the stop-out price, suggesting the recovery lacks grounding in new fundamental evidence or a clear catalyst. Net score is approximately -1 to 0, falling below the threshold for a confident buy.

28. !Oct 8, 7:00 AMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    MDT passes the hard veto check — earnings are 40 days away (not imminent), no fundamental deterioration is visible in the sparse SEC filings, and no going-concern language is present. However, the net signal score is weak: the sector (XLV) is underperforming SPY meaningfully (-6.40pts over 30 days, +1), and there are no insider buys, no unusual call flow, and the drop is only 10.2% (below the 15% mean-reversion threshold). Against those modest positives, the 10Y yield at 5.31% is a structural headwind for a duration-sensitive medtech name (-1), earnings in 15-30 days is not applicable but the 40-day window still introduces uncertainty, elevated 5Y forward inflation expectations (T5YIFR at 1.8σ above trend) add macro pressure (-1), and the re-entry context is critical — the prior trade exited at $93.38, and at $85.69 the stock is still well below the stop-out price, suggesting the recovery lacks grounding in new fundamental evidence or a clear catalyst. Net score is approximately -1 to 0, falling below the threshold for a confident buy.

29. ?Oct 7, 6:21 PMdecisionconsidered

    Agent 20 — SIR Price/Volume — skip

    [distribution] The 20-day PV path traces a textbook down-and-right arc: price has fallen from $91.62 on 2026-09-10 to $85.51 on 2026-10-07 while volume has expanded dramatically — from a 5–10M range in early September to 43.7M, 52.1M, and 55.9M on the final three sessions (2026-10-05 through 2026-10-07). Critically, those three high-volume days are ALL net negative in price (-1.84% net over the sub-path: +1.84%, -1.00%, -1.81%), meaning expanding volume is being consumed by sellers, not buyers. The up-day volume never dominates: the lone up-tick on 2026-10-05 (+1.84%, 43.7M) was immediately overwhelmed by two successive down-days on even higher volume (52.1M and 55.9M), confirming distribution rather than accumulation. Risks: A reclaim of the $88.50–$89.50 prior cluster (late-September support) on a down-volume contraction day would challenge this distribution read and suggest the selling may be exhausting. Additionally, since no explicit bull-regime macro confirmation (broad index level / VIX reading) was supplied, there is residual uncertainty that this is a capitulation flush rather than sustained distribution — a single high-volume reversal day back above $88 would warrant re-evaluation.

30. ?Oct 7, 6:02 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    Medtronic (MDT) is a large-cap, diversified medical device leader with a long track record of stable cash flows and dividends, and no company-specific negative news or deterioration is evident in the available filings or headlines over the past 30 days. The 10.4% drawdown from the 30-day high appears consistent with macro-driven pressure: the 5-year forward inflation rate (T5YIFR) is running 1.8σ above trend, which pressures rate-sensitive and capital-heavy sectors like medical devices through discount-rate expansion. While the SEC filings lack detailed metrics, there is no signal of guidance cuts, accounting irregularities, or structural deterioration to justify treating this as a fundamental breakdown.

31. !Oct 7, 6:02 PMsignalseverity 0.10

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    Medtronic (MDT) is a large-cap, diversified medical device leader with a long track record of stable cash flows and dividends, and no company-specific negative news or deterioration is evident in the available filings or headlines over the past 30 days. The 10.4% drawdown from the 30-day high appears consistent with macro-driven pressure: the 5-year forward inflation rate (T5YIFR) is running 1.8σ above trend, which pressures rate-sensitive and capital-heavy sectors like medical devices through discount-rate expansion. While the SEC filings lack detailed metrics, there is no signal of guidance cuts, accounting irregularities, or structural deterioration to justify treating this as a fundamental breakdown.

32. ?Oct 7, 4:21 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    MDT passes the hard veto check — earnings are 40 days away (not imminent), no fundamental deterioration is visible in the sparse SEC filings, and no going-concern language is present. However, the net signal score is weak: the sector (XLV) is underperforming SPY meaningfully (-6.40pts over 30 days, +1), and there are no insider buys, no unusual call flow, and the drop is only 10.2% (below the 15% mean-reversion threshold). Against those modest positives, the 10Y yield at 5.31% is a structural headwind for a duration-sensitive medtech name (-1), earnings in 15-30 days is not applicable but the 40-day window still introduces uncertainty, elevated 5Y forward inflation expectations (T5YIFR at 1.8σ above trend) add macro pressure (-1), and the re-entry context is critical — the prior trade exited at $93.38, and at $85.69 the stock is still well below the stop-out price, suggesting the recovery lacks grounding in new fundamental evidence or a clear catalyst. Net score is approximately -1 to 0, falling below the threshold for a confident buy.

33. !Oct 7, 4:21 PMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    MDT passes the hard veto check — earnings are 40 days away (not imminent), no fundamental deterioration is visible in the sparse SEC filings, and no going-concern language is present. However, the net signal score is weak: the sector (XLV) is underperforming SPY meaningfully (-6.40pts over 30 days, +1), and there are no insider buys, no unusual call flow, and the drop is only 10.2% (below the 15% mean-reversion threshold). Against those modest positives, the 10Y yield at 5.31% is a structural headwind for a duration-sensitive medtech name (-1), earnings in 15-30 days is not applicable but the 40-day window still introduces uncertainty, elevated 5Y forward inflation expectations (T5YIFR at 1.8σ above trend) add macro pressure (-1), and the re-entry context is critical — the prior trade exited at $93.38, and at $85.69 the stock is still well below the stop-out price, suggesting the recovery lacks grounding in new fundamental evidence or a clear catalyst. Net score is approximately -1 to 0, falling below the threshold for a confident buy.

34. ?Oct 7, 4:21 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MDT is a large-cap medtech incumbent (Medtronic) with a historically stable business, so the 10.2% dip from its 30-day high is not anomalous by triage standards and likely reflects sector-wide pressure rather than company-specific deterioration. However, Health Care (XLV) is notably underperforming — ranked 5th of 11 by 30-day relative strength and down -6.40pts vs SPY over 30 days — suggesting MDT is partially caught in a sector-wide sell-off with no identifiable company-specific recovery catalyst visible. The 10Y yield at 5.31% is a meaningful headwind for a dividend-heavy medtech name, and the elevated 5Y forward inflation rate (1.8σ above trend) adds macro pressure. Earnings are 40 days out (non-factor per framework), and there are no insider buys, no unusual call flow, and no SEC filing metrics to anchor fundamental stability or a recovery thesis.

35. !Oct 7, 4:21 PMsignalseverity 0.10

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MDT is a large-cap medtech incumbent (Medtronic) with a historically stable business, so the 10.2% dip from its 30-day high is not anomalous by triage standards and likely reflects sector-wide pressure rather than company-specific deterioration. However, Health Care (XLV) is notably underperforming — ranked 5th of 11 by 30-day relative strength and down -6.40pts vs SPY over 30 days — suggesting MDT is partially caught in a sector-wide sell-off with no identifiable company-specific recovery catalyst visible. The 10Y yield at 5.31% is a meaningful headwind for a dividend-heavy medtech name, and the elevated 5Y forward inflation rate (1.8σ above trend) adds macro pressure. Earnings are 40 days out (non-factor per framework), and there are no insider buys, no unusual call flow, and no SEC filing metrics to anchor fundamental stability or a recovery thesis.

36. ?Oct 7, 3:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MDT is a large-cap medtech incumbent (Medtronic) with a historically stable business, so the 10.2% dip from its 30-day high is not anomalous by triage standards and likely reflects sector-wide pressure rather than company-specific deterioration. However, Health Care (XLV) is notably underperforming — ranked 5th of 11 by 30-day relative strength and down -6.40pts vs SPY over 30 days — suggesting MDT is partially caught in a sector-wide sell-off with no identifiable company-specific recovery catalyst visible. The 10Y yield at 5.31% is a meaningful headwind for a dividend-heavy medtech name, and the elevated 5Y forward inflation rate (1.8σ above trend) adds macro pressure. Earnings are 40 days out (non-factor per framework), and there are no insider buys, no unusual call flow, and no SEC filing metrics to anchor fundamental stability or a recovery thesis.

37. !Oct 7, 3:20 PMsignalseverity 0.10

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MDT is a large-cap medtech incumbent (Medtronic) with a historically stable business, so the 10.2% dip from its 30-day high is not anomalous by triage standards and likely reflects sector-wide pressure rather than company-specific deterioration. However, Health Care (XLV) is notably underperforming — ranked 5th of 11 by 30-day relative strength and down -6.40pts vs SPY over 30 days — suggesting MDT is partially caught in a sector-wide sell-off with no identifiable company-specific recovery catalyst visible. The 10Y yield at 5.31% is a meaningful headwind for a dividend-heavy medtech name, and the elevated 5Y forward inflation rate (1.8σ above trend) adds macro pressure. Earnings are 40 days out (non-factor per framework), and there are no insider buys, no unusual call flow, and no SEC filing metrics to anchor fundamental stability or a recovery thesis.

38. ?Oct 7, 3:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    MDT passes the hard veto check — earnings are 40 days away (not imminent), no fundamental deterioration is visible in the sparse SEC filings, and no going-concern language is present. However, the net signal score is weak: the sector (XLV) is underperforming SPY meaningfully (-6.40pts over 30 days, +1), and there are no insider buys, no unusual call flow, and the drop is only 10.2% (below the 15% mean-reversion threshold). Against those modest positives, the 10Y yield at 5.31% is a structural headwind for a duration-sensitive medtech name (-1), earnings in 15-30 days is not applicable but the 40-day window still introduces uncertainty, elevated 5Y forward inflation expectations (T5YIFR at 1.8σ above trend) add macro pressure (-1), and the re-entry context is critical — the prior trade exited at $93.38, and at $85.69 the stock is still well below the stop-out price, suggesting the recovery lacks grounding in new fundamental evidence or a clear catalyst. Net score is approximately -1 to 0, falling below the threshold for a confident buy.

39. !Oct 7, 3:20 PMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    MDT passes the hard veto check — earnings are 40 days away (not imminent), no fundamental deterioration is visible in the sparse SEC filings, and no going-concern language is present. However, the net signal score is weak: the sector (XLV) is underperforming SPY meaningfully (-6.40pts over 30 days, +1), and there are no insider buys, no unusual call flow, and the drop is only 10.2% (below the 15% mean-reversion threshold). Against those modest positives, the 10Y yield at 5.31% is a structural headwind for a duration-sensitive medtech name (-1), earnings in 15-30 days is not applicable but the 40-day window still introduces uncertainty, elevated 5Y forward inflation expectations (T5YIFR at 1.8σ above trend) add macro pressure (-1), and the re-entry context is critical — the prior trade exited at $93.38, and at $85.69 the stock is still well below the stop-out price, suggesting the recovery lacks grounding in new fundamental evidence or a clear catalyst. Net score is approximately -1 to 0, falling below the threshold for a confident buy.

40. ?Oct 6, 6:21 PMdecisionconsidered

    Agent 20 — SIR Price/Volume — skip

    [distribution] The 20-day PV path shows a textbook distribution signature: price eroded steadily from $91.89 on 2026-09-09 to $87.09 today (-$4.80, ~5.2%), while volume expanded dramatically — the path drifts decisively down-and-right through 2-D space. Down-day volume dominance is pervasive: every major volume surge since 2026-09-18 (15.4M) has accompanied price declines, culminating in the three most recent sessions (2026-09-30: 26.6M/-0.92%, 2026-10-02: 35.4M/-0.07%, 2026-10-06: 52.1M/-1.00%), where today's 52.1M print is 3.43 standard deviations above the 20-day ADV of 16.0M — sellers are aggressively deploying size into any bid. The sole up-volume burst (2026-10-05: 43.7M/+1.84%) was immediately reversed today on even heavier volume (52.1M/-1.00%), confirming that the prior session's bounce was absorbed and sold — a classic distribution re-test failure. Risks: This bearish read would be invalidated if MDT reclaims the $89.50–$90.77 zone (late-September resistance) on volume materially above today's 52.1M, signaling genuine demand absorption rather than continued distribution. Additionally, the macro context — 5-year breakeven inflation (T5YIFR) printing 2.36, 2.0σ above its 24-month trend — adds a rate-headwind for Health Care, but a sudden dovish policy pivot or sector rotation into defensives could quickly negate the negative price-volume path.

41. ?Oct 5, 6:21 PMdecisionconsidered

    Agent 20 — SIR Price/Volume — skip

    [distribution] The 20-day PV path traces a textbook distribution arc: price drifted steadily lower from $92.39 on 2026-09-08 to a trough near $86.29 on 2026-09-30, while volume expanded dramatically on the down-side — the heaviest sessions were concentrated in the declining phase (2026-09-30: 26.6M, 2026-10-01: 29.3M, 2026-10-02: 35.4M, all on flat-to-down closes), and down-day volume dwarfed up-day volume across the trailing window. Today's bar (2026-10-05: close $87.97, volume 43.8M, z-score +3.53) does register a +1.84% gain, but it arrives after a prolonged down-and-right path in 2-D space — the price is still ~$4.40 below the cluster high near $92–$94 from mid-September, and the explosive volume surge (43.8M vs. 14.2M ADV, >3× normal) on a single up-day is insufficient to reverse a multi-week distribution path under SIR methodology. The path has not yet shown multi-session volume dominance on the up-side to qualify as a bullish reversal or accumulation signal. Risks: The primary invalidation risk is that today's 43.8M-volume up-bar is the first leg of a genuine demand-absorption reversal — if the next 2–3 sessions show sustained above-ADV volume on up-days with closes reclaiming $89–$90, the distribution read would need to be re-evaluated as a potential accumulation base. Additionally, the elevated 5-year inflation breakeven (T5YIFR at 2.35, +1.8σ above trend) poses a macro headwind for rate-sensitive Health Care names like MDT, and any further hawkish repricing could renew selling pressure and reinforce the down-and-right path.

42. ?Oct 5, 10:25 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    MDT is up 1.57% today, a moderate but meaningful intraday move suggesting real buying flow. There are no recent headlines to explain the move, which is common — institutional flows often precede news. With 320 minutes remaining (over 5 hours), there is ample time for continuation into the close. The macro headwind is modest: the 5-year forward inflation rate (T5YIFR) is elevated at 1.8σ above trend, which is a mild negative for rate-sensitive sectors. MDT as a large-cap medical device company has some rate sensitivity (discounted cash flows, capital equipment spending), but it is not acutely rate-sensitive in the way that REITs or utilities are. The move magnitude (1.57%) is below the 2% threshold that would signal strong conviction, so this reads as ordinary momentum rather than a breakout setup. No reversal signals are evident from the data provided. On balance, the momentum is modestly constructive with time remaining and no specific fade catalyst, warranting a slight lean toward continuation but not a high-conviction read.

43. !Oct 5, 10:25 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    MDT is up 1.57% today, a moderate but meaningful intraday move suggesting real buying flow. There are no recent headlines to explain the move, which is common — institutional flows often precede news. With 320 minutes remaining (over 5 hours), there is ample time for continuation into the close. The macro headwind is modest: the 5-year forward inflation rate (T5YIFR) is elevated at 1.8σ above trend, which is a mild negative for rate-sensitive sectors. MDT as a large-cap medical device company has some rate sensitivity (discounted cash flows, capital equipment spending), but it is not acutely rate-sensitive in the way that REITs or utilities are. The move magnitude (1.57%) is below the 2% threshold that would signal strong conviction, so this reads as ordinary momentum rather than a breakout setup. No reversal signals are evident from the data provided. On balance, the momentum is modestly constructive with time remaining and no specific fade catalyst, warranting a slight lean toward continuation but not a high-conviction read.

44. ?Oct 1, 6:21 PMdecisionconsidered

    Agent 20 — SIR Price/Volume — skip

    [distribution] The 20-day PV path tells a clear distributional story: from a price high near $94.17 on 2026-09-04, the scatter path has drifted persistently down-and-right — closes falling from ~$93–94 to ~$86–87 while volume steadily expands. The heaviest volume sessions are all down days: 2026-09-18 (15.4M, −0.69%), 2026-09-22 (14.1M, −1.07%), 2026-09-29 (19.4M, −2.69%), 2026-09-30 (26.6M, −0.92%), and today 2026-10-01 (28.6M, z-score +3.00 vs. 20d ADV of 11.6M). Up-day volume is consistently faint — the strongest UP session in the back half is 2026-09-28 at 22.5M, which was immediately reversed the next day on 19.4M down-volume. Today's fractional +0.17% tick on the highest absolute volume of the entire window (28.6M) does not constitute a reversal; the path remains entrenched in the down-right quadrant of the PV scatter. All three bearish confirmation criteria are satisfied: (1) price has made new multi-week lows near $86, and today's volume is ~2.5× the 20d ADV; (2) the 3-session sub-path (Sep 29–Oct 1) shows net negative price movement (−$87.09 → −$86.29 → +$86.44, net −$0.65) on relentlessly expanding volume (19.4M → 26.6M → 28.6M); (3) the full 20-day path shows an unambiguous down-and-right drift from $94.17/9.0M to $86.44/28.6M. Risks: A decisive reclaim of the $89–90 band (the Sep 21–25 consolidation zone) on volume contracting below the 20d ADV (~11.6M) would signal seller exhaustion and invalidate the distribution read. Additionally, the macro headwind from 5Y breakeven inflation printing 2.36 (2.0σ above trend) is already pressuring rate-sensitive Health Care names like MDT — any surprise dovish pivot or cooler inflation print could lift the sector and overwhelm the technical signal.

45. ?Oct 1, 2:21 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MDT is a large-cap medical device company with a defensible business model, and the 10% dip from its 30-day high lacks a confirmed fundamental catalyst — no negative headlines, no adverse SEC filing metrics, and no clear impairment signal. However, the evidence is notably thin: SEC filings carry no extractable metrics, there are no analyst upgrades or insider cluster buys (the one insider sale by an EVP is a mild negative, and the CAO grant is noise), and no options flow to confirm informed buying. The macro backdrop is modestly headwind-heavy — 10Y at 5.26% is a structural drag on a dividend-paying healthcare name, and the T5YIFR at 2.0σ above trend introduces rate sensitivity. The Health Care sector ranks 3rd of 11 by 30-day relative strength with near-flat relative performance, suggesting the dip is somewhat idiosyncratic, which raises the question of an unconfirmed negative catalyst rather than a clear sector-wide flush to recover from.

46. !Oct 1, 2:21 PMsignalseverity 0.10

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MDT is a large-cap medical device company with a defensible business model, and the 10% dip from its 30-day high lacks a confirmed fundamental catalyst — no negative headlines, no adverse SEC filing metrics, and no clear impairment signal. However, the evidence is notably thin: SEC filings carry no extractable metrics, there are no analyst upgrades or insider cluster buys (the one insider sale by an EVP is a mild negative, and the CAO grant is noise), and no options flow to confirm informed buying. The macro backdrop is modestly headwind-heavy — 10Y at 5.26% is a structural drag on a dividend-paying healthcare name, and the T5YIFR at 2.0σ above trend introduces rate sensitivity. The Health Care sector ranks 3rd of 11 by 30-day relative strength with near-flat relative performance, suggesting the dip is somewhat idiosyncratic, which raises the question of an unconfirmed negative catalyst rather than a clear sector-wide flush to recover from.

47. ?Oct 1, 2:21 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    MDT passes the hard veto check — no fundamental deterioration is evident in recent filings, earnings are 46 days away (outside the 14-day veto window but close enough to apply a -1 headwind), and the sector is not in freefall. Signal scoring yields a marginal net: Health Care ranks 3rd of 11 by 30-day relative strength (sector outperforming slightly, suggesting the 10% drop may be idiosyncratic, -1), earnings in 15-30+ days but still within uncertainty window (-1), elevated 10Y yield at 5.26% is a structural headwind for a capital-intensive medical device name (-1), one minor insider sale (noisy/10b5-1, negligible), and no cluster buy, no unusual call flow, and no options data to provide positive signals. The prior trade was a success (+$199 realized), but the current re-entry lacks grounding in new evidence — no headlines, empty filing metrics, and no insider buying to confirm a revived thesis. Net score is approximately -2 to -3, which does not support a buy. The base rate of ~57% for S&P 500 names is reduced materially by the weak signal stack, pushing below the 0.50 threshold.

48. !Oct 1, 2:21 PMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    MDT passes the hard veto check — no fundamental deterioration is evident in recent filings, earnings are 46 days away (outside the 14-day veto window but close enough to apply a -1 headwind), and the sector is not in freefall. Signal scoring yields a marginal net: Health Care ranks 3rd of 11 by 30-day relative strength (sector outperforming slightly, suggesting the 10% drop may be idiosyncratic, -1), earnings in 15-30+ days but still within uncertainty window (-1), elevated 10Y yield at 5.26% is a structural headwind for a capital-intensive medical device name (-1), one minor insider sale (noisy/10b5-1, negligible), and no cluster buy, no unusual call flow, and no options data to provide positive signals. The prior trade was a success (+$199 realized), but the current re-entry lacks grounding in new evidence — no headlines, empty filing metrics, and no insider buying to confirm a revived thesis. Net score is approximately -2 to -3, which does not support a buy. The base rate of ~57% for S&P 500 names is reduced materially by the weak signal stack, pushing below the 0.50 threshold.

49. ?Oct 1, 12:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MDT is a large-cap medical device company with a defensible business model, and the 10% dip from its 30-day high lacks a confirmed fundamental catalyst — no negative headlines, no adverse SEC filing metrics, and no clear impairment signal. However, the evidence is notably thin: SEC filings carry no extractable metrics, there are no analyst upgrades or insider cluster buys (the one insider sale by an EVP is a mild negative, and the CAO grant is noise), and no options flow to confirm informed buying. The macro backdrop is modestly headwind-heavy — 10Y at 5.26% is a structural drag on a dividend-paying healthcare name, and the T5YIFR at 2.0σ above trend introduces rate sensitivity. The Health Care sector ranks 3rd of 11 by 30-day relative strength with near-flat relative performance, suggesting the dip is somewhat idiosyncratic, which raises the question of an unconfirmed negative catalyst rather than a clear sector-wide flush to recover from.

50. !Oct 1, 12:20 PMsignalseverity 0.10

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MDT is a large-cap medical device company with a defensible business model, and the 10% dip from its 30-day high lacks a confirmed fundamental catalyst — no negative headlines, no adverse SEC filing metrics, and no clear impairment signal. However, the evidence is notably thin: SEC filings carry no extractable metrics, there are no analyst upgrades or insider cluster buys (the one insider sale by an EVP is a mild negative, and the CAO grant is noise), and no options flow to confirm informed buying. The macro backdrop is modestly headwind-heavy — 10Y at 5.26% is a structural drag on a dividend-paying healthcare name, and the T5YIFR at 2.0σ above trend introduces rate sensitivity. The Health Care sector ranks 3rd of 11 by 30-day relative strength with near-flat relative performance, suggesting the dip is somewhat idiosyncratic, which raises the question of an unconfirmed negative catalyst rather than a clear sector-wide flush to recover from.

51. ?Oct 1, 12:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    MDT passes the hard veto check — no fundamental deterioration is evident in recent filings, earnings are 46 days away (outside the 14-day veto window but close enough to apply a -1 headwind), and the sector is not in freefall. Signal scoring yields a marginal net: Health Care ranks 3rd of 11 by 30-day relative strength (sector outperforming slightly, suggesting the 10% drop may be idiosyncratic, -1), earnings in 15-30+ days but still within uncertainty window (-1), elevated 10Y yield at 5.26% is a structural headwind for a capital-intensive medical device name (-1), one minor insider sale (noisy/10b5-1, negligible), and no cluster buy, no unusual call flow, and no options data to provide positive signals. The prior trade was a success (+$199 realized), but the current re-entry lacks grounding in new evidence — no headlines, empty filing metrics, and no insider buying to confirm a revived thesis. Net score is approximately -2 to -3, which does not support a buy. The base rate of ~57% for S&P 500 names is reduced materially by the weak signal stack, pushing below the 0.50 threshold.

52. !Oct 1, 12:20 PMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    MDT passes the hard veto check — no fundamental deterioration is evident in recent filings, earnings are 46 days away (outside the 14-day veto window but close enough to apply a -1 headwind), and the sector is not in freefall. Signal scoring yields a marginal net: Health Care ranks 3rd of 11 by 30-day relative strength (sector outperforming slightly, suggesting the 10% drop may be idiosyncratic, -1), earnings in 15-30+ days but still within uncertainty window (-1), elevated 10Y yield at 5.26% is a structural headwind for a capital-intensive medical device name (-1), one minor insider sale (noisy/10b5-1, negligible), and no cluster buy, no unusual call flow, and no options data to provide positive signals. The prior trade was a success (+$199 realized), but the current re-entry lacks grounding in new evidence — no headlines, empty filing metrics, and no insider buying to confirm a revived thesis. Net score is approximately -2 to -3, which does not support a buy. The base rate of ~57% for S&P 500 names is reduced materially by the weak signal stack, pushing below the 0.50 threshold.

53. ?Sep 30, 6:21 PMdecisionconsidered

    Agent 20 — SIR Price/Volume — skip

    [distribution] The 20-day PV path traces a clear down-and-right drift characteristic of distribution: price has fallen from a cluster around $92–$94 (Sep 2–4, Sep 14) on modest volumes (7.4M–9.3M) to $86.28 today, while selling volume has persistently expanded. The acceleration is striking — down-day volume surged from ~5–8M in mid-September to 10.5M (Sep 16), 15.4M (Sep 18), 14.1M (Sep 22), 19.4M (Sep 29), and a climactic 46.4M on Sep 30 (a z-score of 8.06 versus the 20-day ADV of 10.7M). Up-day volume has been anemic by comparison: the two strongest up sessions were Sep 28 (22.5M, +0.97%) and Sep 14 (9.3M, +3.12%), neither of which arrested the downtrend. All three bearish criteria are met: (1) today's bar is not at a multi-week high so this criterion is not applicable, but (2) the last 3-session sub-path (Sep 28–30) shows net negative price movement (89.50 → 87.09 → 86.28, -$3.22) on expanding volume (22.5M → 19.4M → 46.4M), and (3) the overall 20-day path shows an unambiguous down-and-right drift from $92–$94 to $86.28 on progressively heavier volume — fully confirming a distribution read without needing the bull-regime override. Risks: A sharp reversal on the next session with volume collapsing back toward the 10–12M ADV range would suggest today's 46.4M spike was a capitulation/washout rather than distribution, potentially flipping the read to a bottoming setup. Additionally, if the broader macro environment shifts to a confirmed bull regime (falling 5Y inflation breakevens, VIX below 20), the asymmetric burden-of-proof rule would need to be re-evaluated — though the current T5YIFR print of 2.36 (2.0σ above trend) is an explicit headwind for rate-sensitive Health Care names like MDT.

54. ?Sep 29, 6:21 PMdecisionconsidered

    Agent 20 — SIR Price/Volume — skip

    [distribution] The 20-day PV path tells a clear distributional story. After a brief early-September rally that peaked at $94.17 on 2026-09-04 on modest 9.0M volume, the path pivoted decisively downward: from 2026-09-15 onward, 9 of the final 11 sessions are DOWN days, with expanding volume on the declines — 15.4M on 9/18, 14.1M on 9/22, 10.5M on 9/23, 11.0M on 9/24, and today's 19.3M (z-score +1.97 vs. 20d ADV of 10.7M) — while the sole meaningful up-day in that stretch (9/28, +0.97%) printed 22.5M but immediately failed, giving back the gain entirely on 9/29. The overall path drifts down-and-right — price has fallen from ~$94 to $87.09 while volume expands, a textbook distribution signature under the SIR two-dimensional framework. All three bearish confirmation criteria are met: (1) the 9/28–9/29 two-bar sub-sequence shows a high-volume up day immediately reversed on nearly equivalent volume; (2) the 3-session sub-path (9/25–9/29) shows net negative price movement on rising volume (from 13.1M → 22.5M → 19.3M); and (3) the full 20-day path exhibits a sustained down-and-right drift from $94.17 to $87.09. Risks: A sustained reclaim of the $90–$91 area on volume clearly below the 20-day ADV (i.e., a low-volume, low-supply bounce) would suggest distribution is exhausting and would invalidate the bearish read. Additionally, the elevated 5-year inflation breakeven (T5YIFR at 2.35, +1.9σ above trend) is a macro headwind for rate-sensitive Health Care names like MDT, but any sharp reversal in rate expectations (e.g., a dovish Fed surprise) could spark a short-covering rally that disrupts the distributional path.

55. ?Sep 29, 3:30 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    With only 15 minutes remaining until the forced close, there is very limited time for additional directional movement to develop. The -2.46% move is meaningful and represents real selling pressure, but at this stage of the session the primary risk is mean reversion or end-of-day covering rather than continuation. The macro context (elevated 5Y5Y inflation forward rate at 1.9σ above trend) is mildly negative for rate-sensitive sectors like healthcare/medtech where MDT operates, which is a marginal tailwind for the downside thesis. However, no news catalyst is present to explain the move or sustain it, and with 15 minutes left, profit-taking by intraday shorts and mechanical EOD covering flows are likely to dominate. The time constraint alone is the primary reason to shade below 0.5 — this setup would be more compelling with 60+ minutes remaining.

56. !Sep 29, 3:30 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    With only 15 minutes remaining until the forced close, there is very limited time for additional directional movement to develop. The -2.46% move is meaningful and represents real selling pressure, but at this stage of the session the primary risk is mean reversion or end-of-day covering rather than continuation. The macro context (elevated 5Y5Y inflation forward rate at 1.9σ above trend) is mildly negative for rate-sensitive sectors like healthcare/medtech where MDT operates, which is a marginal tailwind for the downside thesis. However, no news catalyst is present to explain the move or sustain it, and with 15 minutes left, profit-taking by intraday shorts and mechanical EOD covering flows are likely to dominate. The time constraint alone is the primary reason to shade below 0.5 — this setup would be more compelling with 60+ minutes remaining.

57. ?Sep 29, 2:10 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    MDT is down 2.70% intraday with no headline catalyst, suggesting institutional selling or sector rotation rather than a news-driven spike that might reverse. The macro context shows elevated 5Y forward inflation expectations (2.35, ~1.9σ above trend), which is a headwind for rate-sensitive sectors — MDT as a large-cap medtech carries meaningful duration in its valuation, making it reactive to this backdrop. With 95 minutes remaining there is adequate time for continuation into the close, but the absence of a news catalyst and the relatively broad macro pressure rather than a company-specific driver limits conviction. No clear reversal pattern is evident from the data provided. The setup is borderline momentum continuation — no strong reason to expect a fade but also no standout conviction signal. Assigning a modest continuation probability just above threshold.

58. !Sep 29, 2:10 PMsignalseverity -0.03

    Agent 7 — Day Trader — day_trade_skipped

    MDT is down 2.70% intraday with no headline catalyst, suggesting institutional selling or sector rotation rather than a news-driven spike that might reverse. The macro context shows elevated 5Y forward inflation expectations (2.35, ~1.9σ above trend), which is a headwind for rate-sensitive sectors — MDT as a large-cap medtech carries meaningful duration in its valuation, making it reactive to this backdrop. With 95 minutes remaining there is adequate time for continuation into the close, but the absence of a news catalyst and the relatively broad macro pressure rather than a company-specific driver limits conviction. No clear reversal pattern is evident from the data provided. The setup is borderline momentum continuation — no strong reason to expect a fade but also no standout conviction signal. Assigning a modest continuation probability just above threshold.

59. ?Sep 29, 12:45 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    MDT is down 2.75% intraday with no attributable headline, suggesting institutional selling or sector rotation rather than a news-driven spike. The macro backdrop shows the 5-year forward inflation rate (T5YIFR) running 1.9σ above trend — elevated inflation expectations pressure rate-sensitive and defensive sectors, and MDT as a large-cap medtech/healthcare device name can be sensitive to discount rate assumptions on future cash flows. This macro headwind provides a plausible structural reason for the selling pressure to persist. However, several factors limit conviction: (1) no news catalyst means the move could be position-unwinding that is already largely complete; (2) 180 minutes remaining is meaningful time but also enough time for a mean-reversion bounce if the selling exhausts itself; (3) a ~2.75% move in a low-volatility name like MDT is significant and may attract dip buyers near current levels. On balance, the macro context supports the bear case marginally, and with no clear reversal signal or exhaustion evidence, the default lean is modest continuation. Probability set just above 0.5 reflecting a thin edge for continuation rather than high conviction.

60. !Sep 29, 12:45 PMsignalseverity -0.03

    Agent 7 — Day Trader — day_trade_skipped

    MDT is down 2.75% intraday with no attributable headline, suggesting institutional selling or sector rotation rather than a news-driven spike. The macro backdrop shows the 5-year forward inflation rate (T5YIFR) running 1.9σ above trend — elevated inflation expectations pressure rate-sensitive and defensive sectors, and MDT as a large-cap medtech/healthcare device name can be sensitive to discount rate assumptions on future cash flows. This macro headwind provides a plausible structural reason for the selling pressure to persist. However, several factors limit conviction: (1) no news catalyst means the move could be position-unwinding that is already largely complete; (2) 180 minutes remaining is meaningful time but also enough time for a mean-reversion bounce if the selling exhausts itself; (3) a ~2.75% move in a low-volatility name like MDT is significant and may attract dip buyers near current levels. On balance, the macro context supports the bear case marginally, and with no clear reversal signal or exhaustion evidence, the default lean is modest continuation. Probability set just above 0.5 reflecting a thin edge for continuation rather than high conviction.

61. ?Sep 29, 11:15 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    MDT is down 2.30% intraday with no attributable headline, suggesting institutional selling or sector rotation rather than a news-driven spike that might revert quickly. The macro context shows 5-year forward inflation expectations (T5YIFR) running 1.9σ above trend at 2.35, which is a headwind for rate-sensitive, defensive healthcare names like MDT — higher inflation expectations compress multiples on long-duration dividend growers. With 270 minutes remaining (a full session left), there is ample time for continuation. However, the absence of news cuts both ways: without a clear catalyst, the move could be fading at this level, and MDT at ~$87.44 may attract dip buyers in a large-cap medtech. The macro pressure is real but not acute. No reversal pattern is evident from the data given. Overall, modest continuation bias with a probability just above threshold — the rate-sensitive headwind and existing momentum tip the scale slightly toward further downside into the close, but conviction is limited without volume data or a clear fundamental driver.

62. !Sep 29, 11:15 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    MDT is down 2.30% intraday with no attributable headline, suggesting institutional selling or sector rotation rather than a news-driven spike that might revert quickly. The macro context shows 5-year forward inflation expectations (T5YIFR) running 1.9σ above trend at 2.35, which is a headwind for rate-sensitive, defensive healthcare names like MDT — higher inflation expectations compress multiples on long-duration dividend growers. With 270 minutes remaining (a full session left), there is ample time for continuation. However, the absence of news cuts both ways: without a clear catalyst, the move could be fading at this level, and MDT at ~$87.44 may attract dip buyers in a large-cap medtech. The macro pressure is real but not acute. No reversal pattern is evident from the data given. Overall, modest continuation bias with a probability just above threshold — the rate-sensitive headwind and existing momentum tip the scale slightly toward further downside into the close, but conviction is limited without volume data or a clear fundamental driver.

63. ?Sep 29, 10:00 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    MDT is down 1.55% today, a moderate but not extreme move. No headlines are driving this, so it is likely flow/macro driven. The macro context shows the 5-year forward inflation rate (T5YIFR) is running 1.9σ above trend at 2.35, which is a headwind for rate-sensitive sectors — MDT as a large-cap medtech with significant debt financing exposure fits this profile and the elevated inflation expectations could sustain pressure on rate-sensitive names. However, the move at -1.55% is below the 2-5% threshold that signals strong institutional conviction, and with 345 minutes remaining there is ample time but also ample time for mean reversion. There is no reversal pattern evident, no news-driven fade risk, and the macro backdrop modestly supports continued downside. Given the bounded risk profile of the system and no strong reason to expect a fade, a modest continuation probability is warranted, landing at the floor of the actionable range.

64. !Sep 29, 10:00 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    MDT is down 1.55% today, a moderate but not extreme move. No headlines are driving this, so it is likely flow/macro driven. The macro context shows the 5-year forward inflation rate (T5YIFR) is running 1.9σ above trend at 2.35, which is a headwind for rate-sensitive sectors — MDT as a large-cap medtech with significant debt financing exposure fits this profile and the elevated inflation expectations could sustain pressure on rate-sensitive names. However, the move at -1.55% is below the 2-5% threshold that signals strong institutional conviction, and with 345 minutes remaining there is ample time but also ample time for mean reversion. There is no reversal pattern evident, no news-driven fade risk, and the macro backdrop modestly supports continued downside. Given the bounded risk profile of the system and no strong reason to expect a fade, a modest continuation probability is warranted, landing at the floor of the actionable range.

65. ?Sep 28, 6:21 PMdecisionconsidered

    Agent 20 — SIR Price/Volume — skip

    [distribution] The 20-day PV path tells a clear distributive story: after a brief up-and-right accumulation phase peaking at $94.17 on 2026-09-04 (9.0M volume), the path rotated decisively down-and-right — down-days dominated from 2026-09-08 through 2026-09-24, with notably heavy down-day volume (15.4M on 2026-09-18, 14.1M on 2026-09-22, 11.0M on 2026-09-24) driving price from ~$94 to ~$88.51. Today's bar (2026-09-28, close $89.50, 22.5M — a z-score of 3.64 vs the 20d ADV of 10.1M) is a single-session bounce on outsized volume, but the prior path's character — persistent down-day volume dominance and a lower-highs/lower-lows drift through price space — is the dominant signal. Today's isolated high-volume up-day is insufficient to reclassify the overall path as accumulation without multi-session confirmation of a directional shift. Risks: This distribution read would be invalidated if the next 2–3 sessions sustain closes above $90.50–$91.00 on continued above-average volume, forming a cluster-break-up pattern that absorbs the float built up in the $88–$90 range; additionally, a sustained decline in 5-year inflation breakevens (T5YIFR reverting below trend) could provide rate-sensitive tailwinds that shift institutional flows back into MDT, undermining the bearish path narrative.

66. ▣Sep 3, 8:00 PMjournaltime_stop

    Agent 20 — SIR Price/Volume closed long 21 @ $93.10 (+$234.57)

    Time stop: held 92 ≥ 90 days

67. ❖Sep 3, 1:25 PMnewsvia finnhub

    4 Reasons to Buy Medtronic Stock Like There's No Tomorrow

    The medical device maker is on the cusp of a multi-year recovery.

68. ❖Sep 3, 11:37 AMnewsvia finnhub

    Earnings Calendar and Analysis for This Week (June 8-12)

    Check out our earnings calendar for this week, as well as our previews and recaps of the more noteworthy reports.

69. ❖Sep 3, 11:24 AMnewsvia finnhub

    Is Johnson & Johnson Stock Priced For More Growth Than It Has Guided?

    Johnson & Johnson (JNJ) has had a good year. The stock is up 56.5% over the past twelve months against 19.1% for the S&P 500, and at $271.19 sits at about 99% of its 52-week high. The business is still growing. The risk is that the current stock price discounts an acceleration well ahead of management's near-term guidance.

70. ❖Sep 3, 9:54 AMnewsvia finnhub

    Cyberattack & Weak 2026 Outlook Weigh on BSX: Is the Stock a Sell?

    Boston Scientific faces a cyberattack, weaker 2026 guidance and business pressures, raising concerns over its outlook and whether investors should exit.

71. ❖Sep 3, 6:42 AMnewsvia finnhub

    UBS Maintains Buy on Medtronic, Raises Price Target to $110

    UBS analyst Priya Sachdeva maintains Medtronic (NYSE:MDT) with a Buy and raises the price target from $100 to $110.

72. ❖Sep 2, 4:37 PMnewsvia finnhub

    ISRG Stock: The Best House On The Block Costs The Most

    In the world of robotic surgery, one company is both the undisputed leader and the most expensive option, forcing investors to ask if operational excellence is worth the premium.

73. ❖Sep 2, 3:12 PMnewsvia finnhub

    3 AI Stocks To Watch With Up To 45% Earnings Growth

    With central banks lifting interest rates to tackle inflation, investors are hunting for themes that do not rely purely on cheap money to grow. Artificial intelligence in healthcare is one such story. It focuses on software and data rather than heavy assets. This article highlights three Transformative AI Healthcare Stocks from our screener that apply algorithms to diagnostics, treatment decisions, and hospital efficiency. The three stocks that follow are only a starting sample from this...

74. ❖Sep 2, 2:54 PMnewsvia finnhub

    Should Investors Buy SOLV as Growth Improves but Debt Risks Persist?

    Solventum's growth, higher earnings outlook and cost cuts strengthen its case, but heavy debt and 2027 margin risks temper the upside.

75. ❖Sep 2, 2:52 PMnewsvia finnhub

    The Wide Divide Priced Into Boston Scientific Stock

    The market's valuation reflects a wide breadth of potential outcomes for the company, exposing shareholders to the full magnitude of that underlying risk.

76. ❖Sep 2, 12:25 PMnewsvia finnhub

    Medtronic Begins Fiscal 2027 With a Beat-and-Raise, Validating Growth Acceleration, RBC Says

    Medtronic (MDT) delivered a broad-based beat-and-raise to begin fiscal 2027, marking a defining step

77. ❖Sep 2, 12:00 PMnewsvia finnhub

    Is Medtronic Stock Underperforming the Dow?

    While Medtronic has outperformed relative to the Dow over the past three months, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

78. ❖Sep 2, 11:00 AMnewsvia finnhub

    MDT Q1 Earnings Call Focuses on Broad Growth, Raised Guidance

    Medtronic raises its fiscal 2027 outlook as growth broadens across major franchises and newer platforms, with robotics and ablation investments advancing.

79. ✓Sep 2, 10:40 AMdecisionacted

    Agent 7 — Day Trader — decide: buy

    MDT is up 1.63% on the back of a clear fundamental catalyst: the company raised its FY27 outlook following strong Q1 growth, reported mid-session. This is real earnings-driven flow with institutional conviction. The move is moderate in magnitude (not yet exhausted), and the headline appeared around 12:04 ET, meaning price has had time to digest but the full re-rating may not yet be complete with 305 minutes remaining (well into the afternoon session). Supporting the continuation thesis: MDT appears in a 'safe dividend aristocrats' article today, which may bring incremental buying from rotation out of tech as the macro context (elevated 5Y5Y forward inflation at 1.7σ above trend) favors rate-sensitive defensives/dividend payers over duration-sensitive growth. Healthcare/medtech tends to benefit from defensive rotation in such environments. The raised guidance is a sticky catalyst — analysts will be revising estimates, triggering additional buy flow through the session. No reversal pattern is evident from the data provided. The main risk is that 1.63% is already a meaningful single-day move for a large-cap defensive like MDT and some mean-reversion pressure could emerge near the close. On balance, momentum is supported by a clear fundamental driver with supportive macro rotation, yielding moderate-to-solid continuation probability.

80. ❖Sep 2, 10:17 AMnewsvia finnhub

    6 Safe Dividend Aristocrats Yielding Up to 4.7% to Buy as Tech Cools Off

    Medtronic, McCormick and T. Rowe Price are among the stocks that have outperformed the S&P 500 over the past three months—and have dividend yields of at least 3%.

81. ❖Sep 2, 9:00 AMnewsvia finnhub

    REVBIO Publishes in NPJ Microgravity the Results of its TETRANITE® Bone Regeneration Study Conducted Onboard the International Space Station

    LOWELL, Mass., September 02, 2026--RevBio, Inc., has published peer reviewed results of a study in NPJ Microgravity, an open-access journal from the Nature portfolio, showing that its regenerative bone adhesive, TETRANITE®, promotes localized new bone growth in a microgravity environment where the ability to regenerate new bone tissue is significantly compromised.1 A key objective of the study was to compare the ability of TETRANITE, a patented regenerative biomaterial, to generate new bone comp

82. ❖Sep 2, 8:04 AMnewsvia finnhub

    Medtronic raises FY27 outlook after reporting strong Q1 growth

    Medtronic’s cardiac ablation solutions, a sub-segment of its electrophysiology business, was the strongest performer in Q1 with YoY growth of 29.5%.

83. ❖Sep 2, 7:42 AMnewsvia finnhub

    Truist Securities Reiterates Hold on Medtronic, Raises Price Target to $99

    Truist Securities analyst Richard Newitter reiterates Medtronic (NYSE:MDT) with a Hold and raises the price target from $86 to $99.

84. ❖Sep 2, 7:37 AMnewsvia finnhub

    Medtronic Posts Q1 Beat, 2027 Outlook Raise Validates Growth Inflection

    MDT shares rise after Q1 beat and raised FY27 growth guidance. Analysts maintain Buy/Outperform ratings, citing broad-based strength.

85. ❖Sep 2, 7:10 AMnewsvia finnhub

    Company News for Sep 2, 2026

    Companies In The News Are: MDT, MMED, NIO, AAPL.

86. ❖Sep 2, 6:36 AMnewsvia finnhub

    Wells Fargo Maintains Overweight on Medtronic, Raises Price Target to $104

    Wells Fargo analyst Larry Biegelsen maintains Medtronic (NYSE:MDT) with a Overweight and raises the price target from $102 to $104.

87. ❖Sep 2, 6:00 AMnewsvia finnhub

    Medtronic invests $700M in Cornerstone Robotics

    Medtronic will gain rights to distribute the Hong Kong-based company’s Sentire surgical robot in certain markets outside the U.S. alongside its own Hugo system.

88. ❖Sep 2, 4:59 AMnewsvia finnhub

    RBC Capital Reiterates Outperform on Medtronic, Maintains $118 Price Target

    RBC Capital analyst Kendall Au reiterates Medtronic (NYSE:MDT) with a Outperform and maintains $118 price target.

89. ❖Sep 2, 4:27 AMnewsvia finnhub

    Salesforce To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Wednesday

    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Cantor Fitzgerald raised

90. ❖Sep 2, 3:48 AMnewsvia finnhub

    B of A Securities Maintains Buy on Medtronic, Raises Price Target to $110

    B of A Securities analyst Bob Hopkins maintains Medtronic (NYSE:MDT) with a Buy and raises the price target from $95 to $110.

91. ❖Sep 2, 3:30 AMnewsvia finnhub

    Medtronic Analysts Raise Their Forecasts After Upbeat Q1 Earnings

    Medtronic (NYSE:MDT) reported better-than-expected results and raised its FY27 EPS guidance. Analysts are bullish with raised price targets.

92. ❖Sep 2, 2:51 AMnewsvia finnhub

    Stifel Maintains Hold on Medtronic, Raises Price Target to $95

    Stifel analyst Rick Wise maintains Medtronic (NYSE:MDT) with a Hold and raises the price target from $80 to $95.

93. ❖Sep 2, 2:39 AMnewsvia finnhub

    Baird Maintains Neutral on Medtronic, Raises Price Target to $100

    Baird analyst David Rescott maintains Medtronic (NYSE:MDT) with a Neutral and raises the price target from $91 to $100.

94. ❖Sep 1, 10:48 PMnewsvia finnhub

    Dow Dips Over 400 Points As Crude Oil Surges: Investor Sentiment Weakens Further, Fear & Greed Index Moves To ‘Fear’ Zone

    The CNN Business Fear & Greed Index tracks market sentiment, with Tuesday's reading moving to Fear zone as stocks fell on rising yields and fears of Fed rate hikes.

95. ❖Sep 1, 10:07 PMnewsvia finnhub

    How Investors Are Reacting To Merit Medical Systems (MMSI) New Global Operations Leadership Transition

    In August 2026, Merit Medical Systems announced that Sheri Lewis would join as Executive Vice President of Global Operations, bringing three decades of global manufacturing and supply chain experience from SkinHealth Systems, Avantor, Medtronic, and Honeywell, while long-time operations leader Mr. Peterson shifted to a Senior Advisor role through March 2027 to support continuity. This leadership transition highlights Merit's focus on strengthening global operations and supply chain...

96. ▢Sep 1, 8:00 PMjournal

    Agent 7 — Day Trader opened long 31 @ $93.54

97. ▣Sep 1, 8:00 PMjournaltime_stop

    Agent 7 — Day Trader closed long 31 @ $92.43 (-$34.41)

    EOD forced close — day trader never carries overnight

98. ❖Sep 1, 5:55 PMnewsvia finnhub

    Medtronic plc Q1 2027 Earnings Call Summary

    Moby summary of Medtronic plc's Q1 2027 earnings call

99. ❖Sep 1, 5:31 PMnewsvia finnhub

    How To Earn $500 A Month From Medtronic Stock Ahead Of Q1 Earnings

    Medtronic plc will release its first earnings report before the opening bell on Tuesday, Sept. 1. Analysts expect the company to report quarterly earnings of $1.39 per share, up from $1.26 per share in the year-ago period. The consensus estimate...

100. ❖Sep 1, 5:24 PMnewsvia finnhub

     Tesla, Apple, Nvidia, Medtronic, Alumis, Robinhood, Fervo, and More Stocks That Explain Today’s Market

     Tesla trades lower even as investors anticipate the potential entry of Cybercab into the company’s fleet of self-driving cabs.

101. ❖Sep 1, 4:46 PMnewsvia finnhub

     Sector Update: Healthcare Stocks Advance Late Afternoon

     Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index adding 0.6% and

102. ❖Sep 1, 4:00 PMnewsvia finnhub

     Medtronic PLC (MDT) (Q1 2027) Earnings Call Highlights: Strong Revenue Growth and Raised ...

     Medtronic PLC (MDT) reports robust Q1 FY2027 results with 13.7% organic growth, driven by Cardiac Ablation Solutions and broad-based strength, while raising full-year guidance.

103. ❖Sep 1, 3:36 PMnewsvia finnhub

     Stock Market Today: Nasdaq, Dow Slide As Oil Prices Spike; Shell, Exxon Get A Boost (Live Coverage)

     Stock Market Today: The Dow Jones index sinks Tuesday as oil prices jump around 5% on news of new U.S. military attacks on Iran.

104. ❖Sep 1, 2:41 PMnewsvia finnhub

     Sector Update: Healthcare Stocks Rise Tuesday Afternoon

     Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index adding 0.7% and the

105. ❖Sep 1, 1:52 PMnewsvia finnhub

     Apple, Tesla, Nvidia, Medtronic, Alumis, Robinhood, Fervo, and More Stocks That Explain Today’s Market

     Tesla trades lower even as investors anticipate the potential entry of Cybercab into the company’s fleet of self-driving cabs.

106. ❖Sep 1, 1:28 PMnewsvia finnhub

     Medtronic Flirts With A Breakout As Its Spinoff, MiniMed, Hits A Record

     Medtronic stock popped Tuesday as its diabetes spinoff MiniMed rallied after both lifted their full-year guidance.

107. ✓Sep 1, 12:45 PMdecisionacted

     Agent 7 — Day Trader — decide: buy

     MDT has a strong fundamental catalyst: Q1 earnings beat with raised full-year guidance, which is a classic setup for sustained intraday buying as institutional investors digest and accumulate. Headlines confirm the move is earnings-driven with real conviction. The current price is only up ~2%, while one headline references a 5% surge — suggesting there may have been some early fade already from the highs, which tempers enthusiasm slightly. With 180 minutes remaining there is ample time for continuation. The macro backdrop (rising yields, falling futures) is mildly headwinds for the broader market, but MDT as a defensive med-tech with a strong idiosyncratic catalyst is relatively insulated. The Dow weakness noted mid-session has not derailed MDT. The Pi Cardia investment and robotics deal provide additional positive narrative layering. Risks: broad market softness from oil/bond yield pressure could drag all names into the close; the move may have already front-loaded much of the earnings reaction. On balance, the earnings beat + guidance raise is a durable catalyst with institutional buying likely to continue, giving moderate-to-good odds of continuation into the close.

108. ❖Sep 1, 11:43 AMnewsvia finnhub

     Medtronic Q1 Earnings & Revenues Top Estimates, Stock Up in Pre-Market

     MDT beats Q1 earnings and revenue estimates as broad-based growth drives shares higher and prompts a fiscal 2027 guidance boost.

109. ❖Sep 1, 11:14 AMnewsvia finnhub

     Medtronic's Diabetes Spinoff Just Surged. What To Look For In Its Earnings.

     Medtronic stock popped Tuesday as its diabetes spinoff Minimed rallied after both lifted their full-year guidance.

110. ❖Sep 1, 11:14 AMnewsvia finnhub

     Stock Market Today: Dow Falls As Oil Prices Climb; This Medical Technology Name Hits A Buy Point (Live Coverage)

     Stock Market Today: The Dow Jones index sinks Tuesday as oil prices and Treasury yields jump. Nvidia and Micron are morning losers.

111. ❖Sep 1, 11:03 AMnewsvia finnhub

     Medtronic Q1 Earnings Call Highlights

     Medtronic (NYSE:MDT) reported fiscal 2027 first-quarter revenue of $9.8 billion and adjusted earnings per share of $1.45, as the medical-device maker cited broad-based demand, commercial execution and momentum in several growth platforms. Revenue increased 13.7% on both a reported and organic basis

112. ❖Sep 1, 10:38 AMnewsvia finnhub

     Medtronic shares rise 5% after earnings beat and guidance increase

     Medtronic plc (NYSE:MDT) shares rose 5% after the medical device company reported first-quarter fiscal 2027 results above analyst expectations and increased its full-year revenue growth and earnings guidance. Adjusted earnings per share came in at $1.

113. ❖Sep 1, 10:30 AMnewsvia finnhub

     Here's What Key Metrics Tell Us About Medtronic (MDT) Q1 Earnings

     Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended July 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

114. ❖Sep 1, 10:24 AMnewsvia finnhub

     Medtronic plc (MDT) Q1 2027 Earnings Call Transcript

     Medtronic plc (MDT) Q1 2027 Earnings Call September 1, 2026 7:45 AM EDTCompany ParticipantsIngrid Goldberg - Vice President & Head of Investor...

115. ❖Sep 1, 10:09 AMnewsvia finnhub

     Medtronic Raises Full-Year Outlook Following Fiscal First-Quarter Beat

     Medtronic (MDT) lifted its full-year outlook on Tuesday as the medical-device maker reported better-

116. ❖Sep 1, 10:08 AMnewsvia finnhub

     Medtronic (MDT) Invests In Pi Cardia For Complex TAVR Procedures

     Medtronic (NYSE:MDT) has made an investment in Pi-Cardia to expand its structural heart device portfolio for complex transcatheter aortic valve replacement procedures. The agreement gives Medtronic rights to distribute Pi-Cardia's leaflet modification device, the first FDA cleared tool designed to support valve in valve TAVR in patients at risk of coronary obstruction. The move is aimed at addressing more complex aortic valve cases and broadening treatment options for cardiologists and their...

117. ❖Sep 1, 9:53 AMnewsvia finnhub

     Update: US Equity Futures Fall Pre-Bell Tuesday as Global Bond Yields, Oil Prices Rise

     (Updates with economic data, recent oil price movement, world markets' overview and corporate stock

118. ❖Sep 1, 9:49 AMnewsvia finnhub

     Wall Street Lunch: Equities Dance To Bonds' Tune

     Bonds continue to call the market tune, with rising yields pressuring equities, especially growth stocks.

119. ❖Sep 1, 9:26 AMnewsvia finnhub

     Stocks making the biggest moves midday: Palo Alto Networks, Fervo Energy, Chevron, Apple & more

     Here are some of the companies making headlines in midday trading.

120. ❖Sep 1, 9:16 AMnewsvia finnhub

     What Medtronic (MDT)'s Cornerstone Robotics Deal Means For Shareholders

     Medtronic plc recently announced a partnership with Cornerstone Robotics, committing about US$700 million and securing rights to distribute Cornerstone’s Sentire surgical system in select approved markets outside the U.S., where it will be offered alongside Medtronic’s Hugo robotic-assisted surgery platform. This move effectively broadens Medtronic’s robotic surgery portfolio, giving hospitals and surgeons more choice across complementary platforms that can plug into the company’s connected...

121. ▢Aug 31, 8:00 PMjournal

     Agent 7 — Day Trader opened long 31 @ $92.50

122. ▣Aug 31, 8:00 PMjournaltime_stop

     Agent 7 — Day Trader closed long 31 @ $91.96 (-$16.59)

     EOD forced close — day trader never carries overnight

123. ▣Aug 23, 8:00 PMjournaltime_stop

     Agent 5 — Dip Buyer (Evolving) closed long 14 @ $93.38 (+$199.57)

     Time stop: held 97 ≥ 90 days

124. ▣Aug 9, 8:00 PMjournaltarget

     Agent 5 — Dip Buyer (Evolving) closed long 13 @ $89.41 (+$133.70)

     Staged exit (1/2.0): close $89.41 ≥ target $88.84. Selling 13/27 sh, trailing remainder.

125. ?Jul 31, 10:05 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     MDT is down 1.66% today, which is a meaningful but not large intraday move. There are no recent headlines to attribute the move to, and the macro context (elevated mortgage rates) is not directly relevant to MDT as a medical device company. With 340 minutes remaining (essentially the full trading day still ahead), there is ample time for the move to continue or reverse. The move size is below the 2-5% threshold that would indicate strong institutional conviction. Without a clear catalyst, the move could represent sector rotation or broad market pressure, but there is no strong evidence of reversal either. Given the borderline setup with no news, moderate move size, and full day remaining, I lean marginally toward continuation of the downward move, but this is a low-conviction read near the 0.5 threshold.

126. !Jul 31, 10:05 AMsignalseverity -0.02

     Agent 7 — Day Trader — day_trade_skipped

     MDT is down 1.66% today, which is a meaningful but not large intraday move. There are no recent headlines to attribute the move to, and the macro context (elevated mortgage rates) is not directly relevant to MDT as a medical device company. With 340 minutes remaining (essentially the full trading day still ahead), there is ample time for the move to continue or reverse. The move size is below the 2-5% threshold that would indicate strong institutional conviction. Without a clear catalyst, the move could represent sector rotation or broad market pressure, but there is no strong evidence of reversal either. Given the borderline setup with no news, moderate move size, and full day remaining, I lean marginally toward continuation of the downward move, but this is a low-conviction read near the 0.5 threshold.

127. ?Jul 30, 10:41 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     MDT is down 2.22% intraday, a meaningful move suggesting real selling pressure with institutional conviction behind it. The only headline today is a Medtronic-led financing round for CoreMap — a relatively minor capital deployment event that would not typically catalyze a 2%+ drop, so the move appears driven by broader flow or factors not yet surfaced in headlines. Macro context shows 5Y inflation expectations running 1.5σ below trend, which is modestly risk-off for medical devices (a rate-sensitive, valuation-heavy sector) but not a dominant catalyst. With 305 minutes remaining (over 5 hours), there is ample time for continuation, which is a positive factor for following the momentum. However, countervailing considerations temper conviction: (1) the absence of a clear negative catalyst raises the possibility this is an overreaction or thin-volume drift that could fade into the close; (2) low inflation expectations could actually be a mild tailwind for valuation-heavy healthcare names like MDT; (3) no clear technical breakdown narrative is available. On balance, momentum favors modest continuation but without a compelling catalyst or strong macro alignment, this sits near the borderline. Assigning 0.52 — slight edge to continuation given the magnitude and time remaining, but not a high-conviction setup.

128. !Jul 30, 10:41 AMsignalseverity -0.02

     Agent 7 — Day Trader — day_trade_skipped

     MDT is down 2.22% intraday, a meaningful move suggesting real selling pressure with institutional conviction behind it. The only headline today is a Medtronic-led financing round for CoreMap — a relatively minor capital deployment event that would not typically catalyze a 2%+ drop, so the move appears driven by broader flow or factors not yet surfaced in headlines. Macro context shows 5Y inflation expectations running 1.5σ below trend, which is modestly risk-off for medical devices (a rate-sensitive, valuation-heavy sector) but not a dominant catalyst. With 305 minutes remaining (over 5 hours), there is ample time for continuation, which is a positive factor for following the momentum. However, countervailing considerations temper conviction: (1) the absence of a clear negative catalyst raises the possibility this is an overreaction or thin-volume drift that could fade into the close; (2) low inflation expectations could actually be a mild tailwind for valuation-heavy healthcare names like MDT; (3) no clear technical breakdown narrative is available. On balance, momentum favors modest continuation but without a compelling catalyst or strong macro alignment, this sits near the borderline. Assigning 0.52 — slight edge to continuation given the magnitude and time remaining, but not a high-conviction setup.

129. ✓Jul 28, 11:50 AMdecisionacted

     Agent 7 — Day Trader — decide: buy

     MDT is up 3.53% intraday, which represents meaningful institutional flow and conviction. The macro backdrop is modestly supportive — T10YIE at 1.7σ below trend suggests compressed inflation expectations, which is favorable for long-duration assets and generally supportive of healthcare/medtech multiples. The FDA clearance headline for Implicity's ILR ECG analyzer (a cardiac monitoring device) is adjacent to MDT's core cardiac rhythm management business and may be contributing to a sector tailwind lifting MDT sympathetically. No direct MDT-specific catalyst is visible, but absence of headline is not disqualifying given the magnitude of the move. With 235 minutes remaining there is ample time for continuation. No reversal signals are evident — the move is directionally clean. No strong reason to fade. Assigning modest continuation probability above 0.5, held back from higher conviction tier by lack of a confirmed MDT-specific catalyst and the possibility this is a broader medtech sector rotation trade that could stabilize rather than extend.

130. ▢Jul 27, 8:00 PMjournal

     Agent 7 — Day Trader opened long 33 @ $87.19

131. ▣Jul 27, 8:00 PMjournaltime_stop

     Agent 7 — Day Trader closed long 33 @ $86.99 (-$6.60)

     EOD forced close — day trader never carries overnight

132. ?Jul 16, 10:16 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     MDT is up 4.62% intraday with 330 minutes remaining — a substantial move with ample time left in the session. The magnitude of the move suggests real institutional flow/conviction, not noise. No headlines are present, but absence of news is not disqualifying; this type of move in a large-cap like Medtronic often reflects earnings-adjacent catalyst, analyst action, or sector rotation that hasn't been captured in the headline feed. The macro context (5Y breakeven inflation 1.6σ below trend) is mildly supportive for defensive/healthcare names like MDT, as lower inflation expectations reduce discount rate pressure on longer-duration earnings streams. There is no evidence of reversal pattern — the question is whether a 4.62% move is prone to afternoon fade. For MDT, which is a low-volatility healthcare device name, a move of this magnitude is unusual and tends to reflect a durable catalyst rather than speculative froth, which slightly favors continuation over mean-reversion into the close. However, without a clear identifiable catalyst or strong volume confirmation data, and given the risk of profit-taking after a large gap/run, confidence is moderate rather than high. Assigning a mild continuation probability just above threshold.

133. ?Jul 8, 1:36 PMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     MDT is down ~2% today with 130 minutes remaining until the forced close. The move has meaningful size but sits at the lower end of the 2-5% conviction threshold. The single headline present (Neuspera iSNM CMS payment parity) is not directly MDT-related and provides no catalyst in either direction. Macro context shows a flattening yield curve (T10Y2Y 2σ below trend), which tends to favor defensives — MDT as a large-cap medical device company has mild defensive characteristics, but this is a mild tailwind for the sector broadly rather than a specific reversal catalyst for MDT. With 130 minutes remaining there is ample time for continuation, and absent a clear reversal signal (no fade off lows, no obvious bounce pattern described), the default lean is to treat the existing momentum as the best available predictor. However, the lack of a direct negative catalyst for MDT and the mildly supportive macro backdrop for defensives prevent a high-conviction continuation read, keeping probability near the floor for a continuation trade.

134. ?Jul 8, 11:22 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     MDT is down ~1.90% today with no company-specific negative catalyst visible in the headlines — the Neuspera CMS rule note is a competitor/peripheral item, not directly MDT-bearish. The Stryker medtech article frames the sector positively, which slightly cuts against further MDT downside. The macro backdrop shows a flattening yield curve (T10Y2Y 2σ below trend), which is modestly supportive of defensive/medtech names and could attract dip buyers. With 264 minutes remaining there is ample time for either continuation or reversal. The move is meaningful but sub-2%, sitting at the lower threshold of 'real conviction' flow. No strong technical reversal signal is identifiable from available data, but the lack of a negative catalyst and a sector-positive macro read temper continuation confidence. On balance this is a borderline read — no strong reason to fade, but also no clear momentum driver. Assigning minimum threshold probability for a down continuation.

135. ✓Jul 7, 9:45 AMdecisionacted

     Agent 7 — Day Trader — decide: buy

     MDT is up 3.02% intraday, which is a meaningful move representing real institutional flow. With 360 minutes remaining (effectively the full remaining session), there is ample time for continuation. No news headlines are present, but the guidance correctly notes absence of news is not disqualifying — size was taken at these levels with conviction. The macro context shows T10Y2Y at 2.1σ below trend (flattish/slightly inverted yield curve), which favors defensives like MDT (a large-cap medical device/healthcare name) over cyclicals and banks. This is a mild tailwind for the sector. However, a 3% move without a clear catalyst does carry some mean-reversion risk as traders may take profits into the close. Balancing the meaningful momentum signal, the supportive defensive macro backdrop, and the full day of trading remaining against the lack of a fundamental catalyst and potential profit-taking, continuation probability sits modestly above the threshold.

136. ✓Jul 7, 9:31 AMdecisionacted

     Agent 5 — Dip Buyer (Evolving) — pyramid

     Pyramid add-on fired at +11.11% unrealized. Added 9 sh @ $84.78 ($762.98). Position now 27 sh @ weighted avg $79.13.

137. ▢Jul 6, 8:00 PMjournal

     Agent 7 — Day Trader opened long 34 @ $85.57

138. ▣Jul 6, 8:00 PMjournalstop

     Agent 7 — Day Trader closed long 34 @ $84.24 (-$45.22)

     Long stop: close $84.24 ≤ stop $84.29

139. ?Jul 6, 10:05 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     MDT is down 1.61% today, which is a modest but real move. There are no headlines to explain the drop, which means it could be sector rotation, broader market pressure, or quiet institutional selling. The macro context shows 10Y inflation expectations printing 1.6σ below trend — this is a low-inflation signal that is broadly supportive of long-duration sensitive sectors including healthcare/medtech like MDT, which slightly cuts against continued downside. However, the low T10YIE environment also reflects a risk-off or growth-concern tone that could weigh on cyclical medtech. With 340 minutes remaining (essentially a full trading day still ahead), there is ample time for continuation if momentum is real. The move at -1.61% is below the 2-5% threshold where large flow conviction is implied, making this more of a drift than a decisive break. No reversal pattern is evident from the data provided, and no news is present to catalyze a fade. Balancing: modest downside momentum with time remaining argues for mild continuation, but weak macro tailwind for the name and absence of a strong catalyst keeps conviction low. Assigning baseline continuation probability at 0.50 — enough to favor the trade given the system's favorable risk/reward structure, but without strong conviction.

140. ?Jul 2, 3:11 PMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     MDT is up 4.58% today, a meaningful move indicating real institutional flow. However, several factors temper continuation probability: (1) Only 35 minutes remain until the forced close, which severely limits runway for further gains and increases the likelihood of profit-taking/mean reversion into the bell. (2) The macro context shows 10Y inflation expectations (T10YIE) running 1.6σ below trend, which is favorable for long-duration sensitive sectors like healthcare/medtech — a mild tailwind, but not a strong catalyst. (3) No MDT-specific headline is present to explain the move; the JNJ headline references a different ticker and is largely irrelevant. (4) A 4.58% move in MDT without a clear news driver raises the possibility of a gap/spike that gets faded into the close, particularly as institutional desks lock in gains ahead of the session end. (5) With this magnitude of move already realized, the +3% profit target would require MDT to push above ~$85.32, an additional ~3% from current levels in 35 minutes — a very high bar. The risk/reward skews toward caution. Probability falls just below the 0.5 trigger threshold given the time constraint and absence of a sustaining catalyst.

141. ?Jul 1, 10:00 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     MDT is up 1.79% today, a modest but meaningful move. The most recent headline from yesterday evening was actually bearish (stock 'sinks as market gains'), which suggests today's recovery is acting against a negative sentiment backdrop — potentially short covering or a technical bounce rather than fundamental-driven momentum. The macro context (T5YIE 1.6σ below trend) is mildly supportive of rate-sensitive sectors like healthcare/medtech, as lower inflation expectations reduce discount rate pressure on long-duration assets. However, there is no clear catalyst driving this move, and the prior close headline signals the stock was lagging the market. With 345 minutes remaining (essentially a full session still ahead), time is not a constraint. The move is below the 2-5% 'high conviction' threshold, so this reads as ordinary momentum. No strong reversal signals are present, and the bounded risk profile (1.5% stop, 3% target) favors taking the trade at the margin. Probability set just above 0.5 reflecting moderate continuation bias with no strong tailwind.

142. ▣Jun 9, 8:00 PMjournalstop

     options_momentum closed long 100 @ $2.78 (-$98.13)

     Stop: premium $2.78 ≤ trailing floor $2.82 (peak $3.76 × 0.75)

143. ▢Jun 3, 8:00 PMjournal

     options_momentum opened long 100 @ $3.76

144. ▢Jun 3, 8:00 PMjournal

     Agent 20 — SIR Price/Volume opened long 21 @ $81.93

145. ▣Jun 2, 8:00 PMjournalstop

     options_momentum closed long 300 @ $0.58 (-$450.66)

     Stop: premium $0.58 ≤ trailing floor $1.56 (peak $2.08 × 0.75)

146. ▢May 28, 8:00 PMjournal

     options_momentum opened long 300 @ $2.08

147. ▢May 18, 8:00 PMjournal

     Agent 5 — Dip Buyer (Evolving) opened long 13 @ $79.13

148. ▢May 18, 8:00 PMjournal

     Agent 5 — Dip Buyer (Evolving) opened long 14 @ $79.13